A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Melanoma|Non-Small Cell Lung Cancer|Bladder Cancer|Colorectal Cancer|Triple Negative Breast Cancer|Renal Cancer|Head and Neck Cancer|Other Solid Cancers
Interventions: DRUG: Autogene cevumeran|DRUG: Atezolizumab
Sponsor: Genentech, Inc.
Collaborators: BioNTech SE